Refine your search with filters

All-Materials All
Congress-AbstractsCongress Abstracts
Tools-SkillsTools & Skills
PublicationsPublications
Congress-SlidesCongress Presentations
Videos-PodcastsVideos & Podcasts

Quicksearch

P425: Comparison of therapeutic choices in biologic experienced Crohn’s disease and ulcerative colitis patients in Europe: discontinuation rates because of disease improvementsECCO '16 Amsterdam
Year: 2016
Authors:

A. Franceschetti*1, A. Baskett2, H. McKenzie2

1Ipsos healthcare, London, United Kingdom, 2Ipsos Healthcare, London, United Kingdom

P426: Post-induction adalimumab drug levels predict clinical and laboratory remission at week 24 in patients with Crohn’s diseaseECCO '16 Amsterdam
Year: 2016
Authors:

E. Zittan*1, 2, O. B. Kelly1, B. Kabakchiev1, G. C. Nguyen1, K. Croitoru1, A. H. Steinhart1, M. S. Silverberg1

1Mount Sinai Hospital, Zane Cohen Centre for Digestive Diseases; Division of Gastroenterology, Department of Medicine, University of Toronto, Toronto, Canada, 2Institute of Gastroenterology and Liver Diseases, Emek Medical Centre, Afula, Israel

P427: The real-life experience of vedolizumab efficacy and safety in Crohn’s disease: a prospective observational multicentre cohort studyECCO '16 Amsterdam
Year: 2016
Authors:

A. Amiot*1, J. C. Grimaud2, X. Treton3, J. Filippi4, B. Pariente5, L. Peyrin-Biroulet6, A. Noureille7, A. Buisson8, F. Carbonnel9, A. Bourrier10, S. Nancey11, X. Roblin12, P. Marteau13, R. Altwegg14, J. Moreau15, A. Aubourg16, G. Savoye17, A. L. Pelletier18, M. Fumery19, B. Bonaz20, Y. Bouhnik3

1Henri Mondor Hospital, Gastroenterology, Creteil, France, 2Hospital Nord, Department of Gastroenterology and Hepatology, Marseille, France, 3APHP Beaujon, Department of Gastroenterology, Clichy, France, 4Archet 2 Hospital, Department of Gastroenterology, Nice, France, 5CHRU Lille, Department of Gastroenterology, Lille, France, 6CHU Nancy, Department of Gastroenterology and Hepatology, Vandoeuvre-Lès-Nancy, France, 7CHU Hotel Dieu, Department of Gastroenterology, Nantes, France, 8CHU Estaing, Department of Gastroenterology, Clermont-Ferrand, France, 9CHU Bicêtre, Department of Gastroenterology, Le Kremlin-Bicêtre, France, 10APHP St. Antoine Hospital, Department of Gastroenterology, Paris, France, 11Hospital Edouard Herriot, Department of Gastroenterology and Hepatology, Lyon, France, 12University of Saint Etienne, Department of Gastroenterology, Saint Etienne, France, 13Hospital Lariboisière, Department of Gastroenterology, Paris, France, 14CHU Montpellier Saint Eloi Hospital, Department of Gastroenterology, Montpellier, France, 15CHU de Toulouse Hospital de Rangueil, Department of Gastroenterology, Toulouse, France, 16Chu Tours, Department of Gastroenterology and Hepatology, Tours, France, 17CHU Rouen, Department of Gastroenterology, Rouen, France, 18Hospital Bichat Claude Bernard, Department of Gastroenterology, Paris, France, 19Amiens University Hospital, Department of Gastroenterology, Amiens, France, 20Grenoble, gastroenterologie, Grenoble, France

P428: Tofacitinib pharmacokinetics and durability of drug exposure in moderate-to-severe Crohn’s disease patients in Phase 2 induction and maintenance studiesECCO '16 Amsterdam
Year: 2016
Authors:

A. Mukherjee1, C. Deng2, R. Xie2, S.W. Martin3, G. Chan4, M. Moscariello4, W. Niezychowski4, E. Maller*4

1Pfizer Inc, Groton, United States, 2Pfizer Inc, Shanghai, China, 3Pfizer Inc, Cambridge, United States, 4Pfizer Inc, Collegeville, Pennsylvania, United States

P429: The effects of psychiatric treatment in patients with inflammatory bowel disease: a prospective studyECCO '16 Amsterdam
Year: 2016
Authors:

O. Yanartas1, H. c. T. Kanı2, E. Bicakci3, Y. Bez1, M. Banzragch3, Z. Senkal1, I. Kilic4, O. Atug3, K. Kuscu1, N. Imeryuz3, H. Akin*3

1Marmara University, Psychiatry, Istanbul, Turkey, 2Marmara University, Internal Medicine, Istanbul, Turkey, 3Marmara University, Gastroenterology, Istanbul, Turkey, 4Marmara University, Medical Student, Istanbul, Turkey

P430: Prognostic significance of serial faecal calprotectin in inflammatory bowel diseaseECCO '16 Amsterdam
Year: 2016
Authors:

Y. Zhulina1, Y. Cao2, K. Amcoff3, M. Carlson3, C. Tysk1, J. Halfvarson*1

1Örebro University, Department of Gastroenterology, Faculty of Medicine and Health, Örebro, Sweden, 2Örebro University, Clinical Epidemiology and Biostatistics, Faculty of Medicine and Health, Örebro, Sweden, 3Uppsala University, Department of Medical sciences, Gastroenterology Research Group, Uppsala, Sweden

P431: Transabdominal ultrasonography to assess intestinal wall thickness and vascularity appears to predict therapeutic effects of steroid treatment in moderate-to-severe ulcerative colitis patientsECCO '16 Amsterdam
Year: 2016
Authors:

T. Ogashiwa*1, M. Murakami1, S. Tsuda1, M. Nishio1, Y. Kogure1, K. Kasahara1, K. Hirai2, Y. Fukuno2, M. Jin2, A. Hanzawa2, H. Yonezawa2, K. Numata3, H. Kimura1, R. Kunisaki1

1Yokohama City University Medical Centre, Inflammatory Bowel Disease Centre, Yokohama, Japan, 2Yokohama City University Medical Centre, Department of Laboratory Medicine and Clinical Investigation, Yokohama, Japan, 3Yokohama City University Medical Centre, Gastroenterology Centre, Yokohama, Japan

P432: Patient perspectives on biosimilars: a European Federation of Crohn’s and Colitis Associations surveyECCO '16 Amsterdam
Year: 2016
Authors:

L. Peyrin-Biroulet*1, S. Lönnfors2, S. Danese3, X. Roblin4, L. Avedano5, M. Greco5

1University Hospital of Nancy, Department of Gastroenterology, Nancy, France, 2European Federation of Crohn’s and Ulcerative Colitis Associations, Medical Writer, Brussels, Belgium, 3Humanitas University, Department of Gastroenterology, Milan, Italy, 4Saint-Étienne University Hospital, Gastroenterology and Hepatology, Saint-Étienne, France, 5European Federation of Crohn’s and Ulcerative Colitis Associations, Brussels, Belgium

P433: Canadian patient and caregiver perspectives on subsequent entry biologics / biosimilars for inflammatory bowel diseaseECCO '16 Amsterdam
Year: 2016
Authors:

G. Attara*1, R. Bailey2, B. Bressler3, J. Marshall4, R. Panaccione5, G. Aumais6

1Gastrointestinal Society, Vancouver, Canada, 2University of Alberta, Zeidler Ledcor Centre, Department of Medicine, Division of Gastroenterology, Edmonton, Canada, 3University of British Columbia, Medicine, Division of Gastroenterology, St. Paul’s Hospital, Vancouver, Canada, 4McMaster University Medical Centre, Department of Gastroenterology, Hamilton, Canada, 5University of Calgary, Department of Gastroenterology, Foothills Medical Centre, Calgary, Canada, 6CHUM Centre Hospitalier de l’Université de Montréal, Hôpital Maisonneuve-Rosemont, Medicine, Montréal, Canada

P434: Close rectal versus total mesorectal excision in patients with inflammatory bowel disease undergoing proctocolectomy or completion proctectomyECCO '16 Amsterdam
Year: 2016
Authors:

J. de Groof*, O. van Ruler, P. Tanis, W. Bemelman, C. Buskens

Academic Medical Centre, Surgery, Amsterdam, Netherlands

P435: Liver injury associated with anti-tumour necrosis factor therapy in paediatric irritable bowel disease patientsECCO '16 Amsterdam
Year: 2016
Authors:

A. Ricciuto*, B. M. Kamath, T. Walters, P. Church, S. C. Ling, K. Frost, A. Griffiths

Hospital for Sick Children, Division of Gastroenterology, Hepatology and Nutrition, Toronto, Canada

P436: Adalimumab dose escalation is effective and well tolerated in Crohn’s disease patients with secondary loss of response to adalimumabECCO '16 Amsterdam
Year: 2016
Authors:

N. Duveau*, M. Nachury, M. Boualit, R. Gerard, J. Branche, V. Maunoury, P. Desreumaux, B. Pariente

CHU de Lille, Department of Gastroenterology, Lille, France

P437: Confidence, acceptance, and friendship: the 3 winners at Camp Purple Live 2015ECCO '16 Amsterdam
Year: 2016
Authors:

A. McCombie*1, 2, R. Gearry3, R. Lopez4, S. Lönnfors5, A. Day4

1University of Otago, Department of Surgery, Christchurch, New Zealand, 2University of Otago, Department of Medicine, Dunedin, New Zealand, 3University of Otago, Department of Medicine, Christchurch, New Zealand, 4University of Otago, Department of Paediatrics, Christchurch, New Zealand, 5European Federation of Crohn’s and Ulcerative Colitis Associations, Medical Writing, Brussels, Belgium

P438: The inflammatory bowel disease disability index applied to ileal pouch anal anastomoses in New ZealandECCO '16 Amsterdam
Year: 2016
Authors:

Y. Lee1, A. McCombie*1, 2, R. Gearry3, F. Frizelle1, J. Williman4, R. Leong5, T. Eglinton1

1University of Otago, Department of Surgery, Christchurch, New Zealand, 2University of Otago, Department of Medicine, Dunedin, New Zealand, 3University of Otago, Department of Medicine, Christchurch, New Zealand, 4University of Otago, Christchurch, Department of Population Health, Christchurch, New Zealand, 5University of New South Wales, Medicine, Sydney, Australia

P439: Effectiveness of a training programme on motivational interviewing skills applied to inflammatory bowel disease managementECCO '16 Amsterdam
Year: 2016
Authors:

M. Daperno*1, F. Mocciaro2, F. Caprioli3, M. Fantini4, S. Leone5, M. Comberlato6, V. Quercia7

1AO Ordine Mauriziano, Gastroenterology Unit, Torino, Italy, 2ARNAS Ospedale Civico, Gastroenterology Unit, Palermo, Italy, 3IRCCS Ospedale Maggiore, Gastroenterology Unit, Milano, Italy, 4Tor Vergata University, Gastroenterology Department, Roma, Italy, 5EFFCA and AMICI Onlus, Palermo, Italy, 6Bolzano Central Hospital, Department of Gastroenterology, Bolzano, Italy, 7Salesian University Institute, Venezia, Italy

P440: Staged surgical management of complicated ileo-colonic Crohn’s DiseaseECCO '16 Amsterdam
Year: 2016
Authors:

A. P. Mishreki*, F. G. Bergin

Royal Victoria Infirmary, Colorectal Surgery, Newcastle Upon Tyne, United Kingdom

P441: Conjoint analysis for quantification of inflammatory bowel disease patients’ preferences for outcome metricsECCO '16 Amsterdam
Year: 2016
Authors:

W. K. van Deen*1, D. Nguyen1, N. Duran1, E. Kane1, M. G. van Oijen2, D.W. Hommes1

1UCLA Centre for Inflammatory Bowel Diseases, Division of Digestive Diseases, University of California, Los Angeles, California, United States, 2Academic Medical Centre, Amsterdam, Department of Medical Oncology, Amsterdam, Netherlands

P442: Evaluation of safety and efficacy of laparoscopic surgery for ulcerative colitisECCO '16 Amsterdam
Year: 2016
Authors:

M. Yamamoto*, K. Kurachi, T. Harada

Hamamatsu University School of Medicine, Second Department of Surgery, Hamamatsu, Japan

P443: National treatment strategy in inflammatory bowel diseases in Hungary: results from the National Health Insurance Fund Prescription DatabaseECCO '16 Amsterdam
Year: 2016
Authors:

Z. Kurti*1, L. Gonczi1, P. A. Golovics1, B. Lovasz1, P. Fadgyas-Freyler2, J. Gimesi-Orszagh2, G. B. Korponai2, Z. Vegh1, P. Lakatos1

1Semmelweis University, First Department of Medicine, Budapest, Hungary, 2National Health Insurance Fund (OEP), Strategic Analysis Department, Budapest, Hungary

P444: High-dose intravenous iron isomaltoside infusion is not associated with an increase in intact fibroblast growth factor 23 (iFGF23) in patients with inflammatory bowel diseaseECCO '16 Amsterdam
Year: 2016
Authors:

J. F. Dahlerup*1, S. Lindgren2

1Aarhus University Hospital, Department of Hepatology and Gastroenterology, Aarhus, Denmark, 2Lund University, University Hospital MAS, Department of Gastroenterology, Malmö, Sweden